8-K: Xencor Dismisses RSM, Appoints KPMG as New Independent Auditor Following Material Weaknesses

Xencor, Inc. announces the dismissal of RSM US LLP as its independent auditor and the appointment of KPMG LLP, following the identification of material weaknesses in internal control over financial reporting.

Summary

• Xencor, Inc. dismissed RSM US LLP as its independent registered public accounting firm, effective immediately on February 27, 2025.
• The dismissal was approved by the Audit Committee of the Board of Directors.
• RSM's reports for the fiscal years ended December 31, 2024 and 2023 indicated material weaknesses in the company's internal control over financial reporting.
• These weaknesses related to the review of accounting treatment for proceeds from the sale of future royalties and the evaluation of certain tax legislation, leading to a restatement of prior financial statements.
• Additionally, a material weakness was identified in the impairment analysis of its equity investment in Zenas for the quarterly periods ended March 31, 2024 and June 30, 2024, which was remediated by September 30, 2024.
• Xencor's Audit Committee approved the appointment of KPMG LLP as the new independent registered public accounting firm, effective March 3, 2025.
• The company initiated a request-for-proposal process in September 2024 to solicit proposals from leading national accounting firms.

Sentiment

Score: 3

Explanation: The announcement of a change in auditors due to material weaknesses in internal control is generally viewed negatively by the market. While the company is taking steps to address the issues, the restatement of financials and the auditor change create uncertainty.

Positives

• Xencor has implemented a remediation plan to address the identified material weaknesses in its internal control over financial reporting.
• The company proactively initiated a request-for-proposal process to find a new independent auditor.
• The material weakness related to the impairment analysis of its equity investment in Zenas was remediated as of the quarterly period ended September 30, 2024.

Negatives

• RSM's reports for the fiscal years ended December 31, 2024 and 2023 indicated material weaknesses in the company's internal control over financial reporting.
• The company had to restate its audited financial statements for the year ended December 31, 2023, and unaudited financial statements for the quarterly periods ended March 31, 2024, June 30, 2024, and September 30, 2024.
• RSM has recalled its reports, dated February 28, 2024, on the company's 2023 internal control over financial reporting and the 2023 financial statements.

Risks

• Failure to fully remediate the identified material weaknesses could lead to further financial reporting issues.
• The transition to a new auditor could present challenges and require additional resources.
• The restatement of prior financial statements could negatively impact investor confidence.

Industry Context

Changes in auditors, especially following material weaknesses, are not uncommon in the biopharmaceutical industry, which often involves complex accounting treatments for research and development expenses, licensing agreements, and royalty streams. Companies in this sector are under intense scrutiny regarding their financial reporting, given the high-risk, high-reward nature of drug development.

Comparison to Industry Standards

• The identification of material weaknesses in internal control over financial reporting is a concern, as it indicates potential vulnerabilities in the company's financial processes.
• Companies like Amgen, Gilead Sciences, and Regeneron, which are larger and more established, generally maintain robust internal controls to ensure accurate financial reporting.
• Smaller biotech firms, especially those reliant on complex financing arrangements like royalty sales, may face greater challenges in maintaining adequate internal controls.
• The appointment of KPMG, a Big Four accounting firm, signals a commitment to strengthening financial oversight and controls, aligning Xencor with industry best practices.

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the auditor change and restatement of financials.
• Employees in the finance and accounting departments may face increased scrutiny and workload during the transition.
• The company's reputation with investors and partners could be temporarily affected.

Next Steps

• Xencor will file RSM's letter to the SEC regarding their agreement with the company's disclosures.
• KPMG will begin its audit services for the fiscal year ending December 31, 2025.
• Xencor will continue to implement its remediation plan to address the material weaknesses.

Key Dates